UK: A secondary analysis of the FINEARTS-HF randomized clinical trial evaluated the performance of the PREDICT-HFpEF model in ...

We investigated the non-steroidal MRA, finerenone, in patients with HFmrEF/HFpEF in the FINEARTS-HF trial, and a significant positive impact on outcomes was observed." FINEARTS-HF was a double ...

BioCardia (BCDA) announced completion of source data verification and freezing of primary outcomes data in the double-blind randomized ...

The multicenter trial will enroll over 1,000 patients across 24 medical centers in Spain to confirm whether ReDS-guided heart failure (HF) management improves 30-day patient outcomes compared to ...

The need to intensify oral diuretic therapy in patients who have heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is significantly decreased with finerenone (Kerendia; ...

In the METEORIC-HF trial, omecamtiv was unable to show an improved performance in exercise capacity among patients with heart failure with reduced ejection fraction (HFrEF) compared to placebo.

that can enhance uptake of guideline-directed medical therapy (GDMT), the AIM-POWER trial shows. Compared with usual care, use of the BiovitalsHF platform (Biofourmis) provided a greater increase in ...

Summary of key findings: The DELTA-HF feasibility study is continuing to enroll patients in Europe. A randomized controlled trial will begin in the United States, Canada and Europe later this year.

The ALLAY-HFrEF trial will support the company’s first pivotal trial, ALLAY-HF (NCT05685303), which is ... We welcome Gilde Healthcare and Omega to this strong partnership.” ...

BOSTON, Feb. 24, 2025 /PRNewswire/ -- At the THT conference, Dr. Jesus Alvarez-Garcia, MD, PhD, head of Advanced Heart Failure Unit at Ramón y Cajal Hospital in Madrid, announced the launch of ...